

Heidelinde Fiegl

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2987179/heidelinde-fiegl-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97
papers

6,133
citations

39
h-index

77
g-index

100
ext. papers

6,778
ext. citations

6.7
avg, IF

4.97
L-index

#	Paper	IF	Citations
97	A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort.. <i>Breast</i> , 2022 , 63, 1-8	3.6	0
96	Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort. <i>Acta Oncologica</i> , 2021 , 60, 187-190	3.2	
95	Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA125 - a Prospective Cohort Trial. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021 , 81, 1047-1054	2.4	
94	The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents.. <i>Cell Death and Disease</i> , 2021 , 12, 1151	9.8	1
93	The miR-34 family and its clinical significance in ovarian cancer. <i>Journal of Cancer</i> , 2020 , 11, 1446-1456	4.5	18
92	High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome. <i>International Journal of Cancer</i> , 2020 , 146, 2007-2018	7.5	21
91	Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer. <i>Scientific Reports</i> , 2020 , 10, 20412	4.9	3
90	TNF β signalling predicts poor prognosis of patients with endometrial cancer. <i>Carcinogenesis</i> , 2020 , 41, 1065-1073	4.6	5
89	Quality management at the national biobanking level - establishing a culture of mutual trust and support: the BBMRI.at example. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, e301-e305	5.9	4
88	Clinical Impact of RANK Signalling in Ovarian Cancer. <i>Cancers</i> , 2019 , 11,	6.6	4
87	NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer. <i>Tumor Biology</i> , 2019 , 41, 1010428319830002	2.9	5
86	Glucocorticoid Receptor-Deficient Foxp3 Regulatory T Cells Fail to Control Experimental Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 472	8.4	18
85	Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer. <i>Cancer Science</i> , 2019 , 110, 1117-1126	6.9	5
84	BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. <i>British Journal of Cancer</i> , 2018 , 119, 683-692	8.7	16
83	Inborn-like errors of metabolism are determinants of breast cancer risk, clinical response and survival: a study of human biochemical individuality. <i>Oncotarget</i> , 2018 , 9, 31664-31681	3.3	5
82	Clinical impact of BRCA1 and BRCA2 mRNA expression in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17533-e17533	2.2	
81	and mutation status associates with and expression in ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 17501-17511	3.3	54

80	Evaluation of Vav3.1 as prognostic marker in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 2067-2076	4.9	7
79	Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1. <i>Journal of Comparative Effectiveness Research</i> , 2017 , 6, 563-574	2.1	4
78	Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. <i>BMC Medicine</i> , 2017 , 15, 116	11.4	25
77	FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3. <i>Oncogene</i> , 2017 , 36, 6190-6203	9.2	20
76	Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy. <i>Molecular Therapy - Oncolytics</i> , 2016 , 3, 16021	6.4	39
75	High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing. <i>European Journal of Human Genetics</i> , 2016 , 24, 258-62	5.3	2
74	Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer. <i>BMC Cancer</i> , 2016 , 16, 102	4.8	47
73	High prevalence of side population in human cancer cell lines. <i>Oncoscience</i> , 2016 , 3, 85-87	0.8	10
72	KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients. <i>Oncotarget</i> , 2016 , 7, 84705-84717	3.3	10
71	Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 37205-37214	3.3	4
70	Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. <i>Oncotarget</i> , 2016 , 7, 40221-40232	4.3	7
69	Reduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients. <i>BMC Cancer</i> , 2016 , 16, 821	4.8	17
68	Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers. <i>BMC Cancer</i> , 2016 , 16, 589	4.8	12
67	Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. <i>BMC Cancer</i> , 2015 , 15, 33	4.8	31
66	Epigenetics in the perioperative period. <i>British Journal of Pharmacology</i> , 2015 , 172, 2748-55	8.6	31
65	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. <i>Genome Medicine</i> , 2015 , 7, 108	14.4	110
64	Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab. <i>Oncotarget</i> , 2015 , 6, 25017-23	3.3	14
63	In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. <i>European Journal of Immunology</i> , 2014 , 44, 2247-62	6.1	81

62	miR-21-3p is a positive regulator of L1CAM in several human carcinomas. <i>Cancer Letters</i> , 2014 , 354, 455-669	33
61	Lidocaine and ropivacaine, but not bupivacaine, demethylate deoxyribonucleic acid in breast cancer cells in vitro. <i>British Journal of Anaesthesia</i> , 2014 , 113 Suppl 1, i32-8	5.4 43
60	High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. <i>BMC Cancer</i> , 2014 , 14, 257	4.8 51
59	Association of TNFRSF10D DNA-methylation with the survival of melanoma patients. <i>International Journal of Molecular Sciences</i> , 2014 , 15, 11984-95	6.3 5
58	Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. <i>Oncotarget</i> , 2014 , 5, 462-72	3.3 61
57	Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e15173-e15173	2.2
56	Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens. <i>BMC Cancer</i> , 2013 , 13, 156	4.8 13
55	Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. <i>PLoS Medicine</i> , 2013 , 10, e1001551	11.6 100
54	GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 1050-5	3.5 16
53	Long non-coding RNAs as targets for cytosine methylation. <i>RNA Biology</i> , 2013 , 10, 1003-8	4.8 107
52	Polymorphisms in the gene regions of the adaptor complex LAMTOR2/LAMTOR3 and their association with breast cancer risk. <i>PLoS ONE</i> , 2013 , 8, e53768	3.7 8
51	HE4 is an independent prognostic marker in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2012 , 126, 186-91	4.9 70
50	Lidocaine time- and dose-dependently demethylates deoxyribonucleic acid in breast cancer cell lines in vitro. <i>British Journal of Anaesthesia</i> , 2012 , 109, 200-7	5.4 85
49	Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. <i>British Journal of Cancer</i> , 2012 , 106, 189-98	8.7 38
48	Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. <i>Genome Medicine</i> , 2012 , 4, 24	14.4 127
47	Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. <i>PLoS ONE</i> , 2012 , 7, e40466	3.7 44
46	Ovarian cancer stem cells. <i>Neoplasma</i> , 2012 , 59, 747-55	3.3 35
45	FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma. <i>Molecular Biology of the Cell</i> , 2012 , 23, 2226-34	3.5 22

44	Mutual antagonism of TGF-beta and Interleukin-2 in cell survival and lineage commitment of induced regulatory T cells. <i>Cell Death and Differentiation</i> , 2012 , 19, 1277-87	12.7	17
43	The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. <i>PLoS Genetics</i> , 2012 , 8, e1002517	6	88
42	Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 8353-63	6.3	26
41	The N-terminally truncated p53 isoform Δ0p53 influences prognosis in mucinous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2012 , 22, 372-9	3.5	30
40	Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. <i>Oncogene</i> , 2011 , 30, 4038-49	9.2	36
39	DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 121, 24-31	4.9	38
38	The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies. <i>Journal of Clinical Bioinformatics</i> , 2011 , 1,		31
37	Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. <i>Cancer Science</i> , 2010 , 101, 1059-66	6.9	54
36	Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. <i>Oncogene</i> , 2010 , 29, 1997-2004	9.2	60
35	E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer. <i>Cancer Research</i> , 2010 , 70, 4613-23	10.1	29
34	Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. <i>Blood</i> , 2010 , 115, 995-1005		45
33	Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2010 , 59, 1813-23	7.4	3
32	DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. <i>Breast Cancer Research and Treatment</i> , 2010 , 120, 345-55	4.4	9
31	Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. <i>International Journal of Cancer</i> , 2009 , 124, 2353-60	7.5	25
30	Hybridization of binary monolayers of single stranded oligonucleotides and short blocking molecules. <i>Surface Science</i> , 2009 , 603, 620-624	1.8	9
29	Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 3494-502	12.9	33
28	Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. <i>PLoS ONE</i> , 2008 , 3, e2656	3.7	116
27	SFRP2 methylation in fecal DNA--a marker for colorectal polyps. <i>International Journal of Colorectal Disease</i> , 2008 , 23, 15-9	3	59

26	HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. <i>International Journal of Cancer</i> , 2008 , 123, 725-9	7.5	86
25	Cancer diagnosis, risk assessment and prediction of therapeutic response by means of DNA methylation markers. <i>Disease Markers</i> , 2007 , 23, 89-96	3.2	12
24	Epigenetic stem cell signature in cancer. <i>Nature Genetics</i> , 2007 , 39, 157-8	36.3	909
23	FBXW7/hCDC4 is a general tumor suppressor in human cancer. <i>Cancer Research</i> , 2007 , 67, 9006-12	10.1	393
22	Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. <i>Cancer Letters</i> , 2007 , 246, 253-61	9.9	29
21	Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. <i>Cancer Research</i> , 2006 , 66, 7355-60	10.1	26
20	Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. <i>Cancer Research</i> , 2006 , 66, 29-33	10.1	153
19	The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 8326-31	12.9	422
18	Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. <i>Cancer Research</i> , 2005 , 65, 1141-5	10.1	205
17	DNA methylation in serum and tumors of cervical cancer patients. <i>Clinical Cancer Research</i> , 2004 , 10, 565-71	12.9	112
16	Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. <i>Clinical Chemistry</i> , 2004 , 50, 2171-3	5.5	34
15	Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. <i>Cancer Research</i> , 2004 , 64, 3807-13	10.1	284
14	DNA hypomethylation is prevalent even in low-grade breast cancers. <i>Cancer Biology and Therapy</i> , 2004 , 3, 1225-31	4.6	107
13	DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. <i>Clinical Chemistry</i> , 2004 , 50, 1065-8	5.5	22
12	Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. <i>Clinical Cancer Research</i> , 2004 , 10, 3396-400	12.9	58
11	DNA hypomethylation and ovarian cancer biology. <i>Cancer Research</i> , 2004 , 64, 4472-80	10.1	193
10	Cyclin E dysregulation and chromosomal instability in endometrial cancer. <i>Oncogene</i> , 2004 , 23, 4187-92	9.2	49
9	Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. <i>Gynecologic Oncology</i> , 2004 , 93, 407-16	4.9	57

8	Prognostic DNA methylation marker in serum of cancer patients. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1022, 44-9	6.5	71
7	CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. <i>International Journal of Cancer</i> , 2004 , 109, 163-6	7.5	67
6	A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. <i>Cancer Letters</i> , 2004 , 209, 231-6	9.9	19
5	Interferon-gamma expression is an independent prognostic factor in ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2004 , 191, 1598-605	6.4	69
4	Methylation changes in faecal DNA: a marker for colorectal cancer screening?. <i>Lancet, The</i> , 2004 , 363, 1283-5	40	231
3	Attenuation of cell adhesion in lymphocytes is regulated by CYTIP, a protein which mediates signal complex sequestration. <i>EMBO Journal</i> , 2003 , 22, 1014-24	13	54
2	MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. <i>British Journal of Cancer</i> , 2003 , 89, 1934-9	8.7	52
1	DNA methylation in serum of breast cancer patients: an independent prognostic marker. <i>Cancer Research</i> , 2003 , 63, 7641-5	10.1	222